Ilex Oncology
Executive Summary
Richard Bryce, MD, is appointed to medical affairs director overseeing development of the humanized monoclonal antibody Campath (alemtuzumab) in oncologic and non-oncologic indications. Bryce most recently served as medical director at Scotia Pharmaceuticals